Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.56 |
| ▸ | CA2 | P00918 | 3/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | BCL9 | O00512 | 1/20 | 0.47 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.47 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.46 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.46 |
| ▸ | STS | P08842 | 4/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3210161 | 1.00 | KMT2A (0.56) | KMT2ASMN1; SMN2CA2NPC1RAB9A | |
| SCHEMBL168079 | 1.00 | KMT2A (0.56) | KMT2ASMN1; SMN2CA2NPC1RAB9A | |
| SCHEMBL8934481 | 1.00 | KMT2A (0.56) | KMT2ASMN1; SMN2CA2NPC1RAB9A | |
| SCHEMBL27917274 | 1.00 | KMT2A (0.56) | KMT2ASMN1; SMN2CA2NPC1RAB9A | |
| SCHEMBL167269 | 1.00 | KMT2A (0.56) | KMT2ASMN1; SMN2CA2NPC1RAB9A | |
| SCHEMBL29048864 | 1.00 | KMT2A (0.56) | KMT2ASMN1; SMN2CA2NPC1RAB9A | |
| SCHEMBL5706182 | 0.98 | KMT2A (0.54) | KMT2ASMN1; SMN2CA2NPC1RAB9A | |
| SCHEMBL9780313 | 0.98 | KMT2A (0.54) | KMT2ASMN1; SMN2CA2NPC1RAB9A | |
| SCHEMBL6902490 | 0.98 | KMT2A (0.54) | KMT2ASMN1; SMN2CA2NPC1RAB9A | |
| SCHEMBL158351 | 0.98 | KMT2A (0.54) | KMT2ASMN1; SMN2CA2NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1103 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10647947-B2 | Detergent composition | NOVOZYMES A/S (DK) | 2020-05-12 | — | — | US | claimed |
| US-12630812-B2 | Subtilase variants and polynucleotides encoding same | NOVOZYMES A/S (DK) | 2026-05-19 | — | — | US | disclosed |
| US-20260132388-A1 | LIPASE VARIANTS AND MICROCAPSULE COMPOSITIONS COMPRISING SUCH LIPASE VARIANTS | NOVOZYMES A/S (DK) | 2026-05-14 | — | — | US | disclosed |
| EP-4739760-A1 | WASHING METHOD FOR REMOVING PROTEINACEOUS STAINS | Novozymes A/S (DK) | 2026-05-13 | — | — | EP | disclosed |
| EP-4729596-A2 | DETERGENT COMPOSITION COMPRISING AMYLASE AND PROTEASE VARIANTS | Novozymes A/S (DK) | 2026-04-22 | — | — | EP | disclosed |
| US-12606810-B2 | Subtilase variants and compositions comprising same | NOVOZYMES A/S (DK) | 2026-04-21 | — | — | US | disclosed |
| US-12595442-B2 | Lipase variants and compositions comprising surfactant and lipase variant | NOVOZYMES A/S (DK) | 2026-04-07 | — | — | US | disclosed |
| EP-4717756-A2 | LIPASE VARIANTS AND DETERGENT COMPOSITIONS | Novozymes A/S (DK) | 2026-04-01 | — | — | EP | disclosed |
| US-12590273-B2 | Stabilized glycoside hydrolase variants | NOVOZYMES A/S (DK) | 2026-03-31 | — | — | US | disclosed |
| EP-3455352-B1 | VARIANT POLYPEPTIDES WITH IMPROVED PERFORMANCE AND USE OF THE SAME | NOVOZYMES AS (DK) | 2026-03-18 | — | — | EP | disclosed |
| EP-1275708-A1 | Two-agent type liquid bleaching compositions | Kao Corporation (JP) | 2003-01-15 | — | — | EP | disclosed |
| US-20010046951-A1 | Bleaching detergent composition | KAO CORPORATION (JP) | 2001-11-29 | — | — | US | disclosed |
| CN-1312359-A | Bleaching detergent composition | KAO CORP (JP) | 2001-09-12 | — | — | CN | disclosed |
| EP-1122300-A1 | Bleaching detergent composition | Kao Corporation (JP) | 2001-08-08 | — | — | EP | disclosed |
| EP-0700900-B1 | PROCESS FOR PRODUCING ACYLOXYBENZENESULFONIC ACID OR SALT THEREOF | KAO CORP (JP) | 1999-11-03 | — | — | EP | disclosed |
| US-5606104-A | SULFONATING THE CORRESPONDING ACYLOXYBENZENE | KAO CORPORATION (JP) | 1997-02-25 | — | — | US | disclosed |
| CN-1125939-A | Process for producing acyloxybenzenesulfonic acid or salt thereof | KAO CORP (JP) | 1996-07-03 | — | — | CN | disclosed |
| EP-0700900-A1 | PROCESS FOR PRODUCING ACYLOXYBENZENESULFONIC ACID OR SALT THEREOF | Kao Corporation (JP) | 1996-03-13 | — | — | EP | disclosed |
| US-5069828-A | PROCESS FOR PREPARING BENZENESULFONATE SALTS | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1991-12-03 | — | — | US | disclosed |
| EP-0402048-A1 | Improved process for preparing benzenesulfonate salts | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1990-12-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260132388-A1 | LIPASE VARIANTS AND MICROCAPSULE COMPOSITIONS COMPRISING SUCH LIPASE VARIANTS | LIPE, LPL, PNLIP | KMT2A 2359/4885SMN1; SMN2 2852/4885CA2 4092/4885 |
| US-12590273-B2 | Stabilized glycoside hydrolase variants | IDUA, IDE, TREH | KMT2A 3458/4885SMN1; SMN2 2305/4885CA2 2739/4885 |
| US-12606810-B2 | Subtilase variants and compositions comprising same | PRSS1, CTRL, TMPRSS11D | KMT2A 3177/4885SMN1; SMN2 1591/4885CA2 2020/4885 |
| US-12630812-B2 | Subtilase variants and polynucleotides encoding same | RNASE1, PEPD, DPP9 | KMT2A 3283/4885SMN1; SMN2 657/4885CA2 3419/4885 |
| US-12595442-B2 | Lipase variants and compositions comprising surfactant and lipase variant | LPL, PNLIP, LIPE | KMT2A 2610/4885SMN1; SMN2 3820/4885CA2 3999/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.